The avoidance of repeated acute kidney injury (AKI), the use of reno-protective medications such as renin-angiotensin-aldosterone system blockers in patients with hypertension or sodium glucose cotransporter 2 inhibitors in patients with diabetes mellitus (DM), and the prompt correction of complications such as anemia, metabolic acidosis, and electrolyte imbalances, are important approaches for retarding CKD and reducing morbidity/mortality [5]. Here, SLC5A2 is linked to acute kidney injury.